Abstract
We read with interest the recent article by van Rijssen and associates 1 van Rijssen T.J. van Dijk E.H.C. Scholz P. et al. Crossover to photodynamic therapy or micropulse laser after failure of primary treatment of chronic central serous chorioretinopathy. Am J Ophthalmol. 2020; 216: 80-89 Abstract Full Text Full Text PDF PubMed Scopus (9) Google Scholar regarding their REPLACE Trial. The PLACE Trial randomized eyes with chronic central serous chorioretinopathy (CSCR) to either half-dose photodynamic therapy (HD-PDT) or high-density subthreshold micropulse laser (HSML). The reported outcomes favored the HD-PDT group. 2 van Dijk E.H.C. Fauser S. Breukink M.B. et al. Half-dose photodynamic therapy versus high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy: The PLACE Trial. Ophthalmology. 2018; 125: 1547-1555 Abstract Full Text Full Text PDF PubMed Scopus (104) Google Scholar More recently, van Rijssen and associates 1 van Rijssen T.J. van Dijk E.H.C. Scholz P. et al. Crossover to photodynamic therapy or micropulse laser after failure of primary treatment of chronic central serous chorioretinopathy. Am J Ophthalmol. 2020; 216: 80-89 Abstract Full Text Full Text PDF PubMed Scopus (9) Google Scholar conducted the REPLACE Trial, where patients with persistent subretinal fluid exiting the PLACE trial were invited to participate. Those eyes that had failed HD-PDT were treated with HSML and those that had failed HSML were treated with HD-PDT. Again, the reported outcomes favored the HD-PDT group. Crossover to Photodynamic Therapy or Micropulse Laser After Failure of Primary Treatment of Chronic Central Serous Chorioretinopathy: The REPLACE TrialAmerican Journal of OphthalmologyVol. 216PreviewTo assess whether chronic central serous chorioretinopathy (cCSC) patients without a complete resolution of subretinal fluid (SRF) after either half-dose photodynamic therapy (PDT) or high-density subthreshold micropulse laser (HSML) treatment may benefit from crossover treatment. Full-Text PDF Open AccessReply to Comment on: Crossover to Photodynamic Therapy or Micropulse Laser After Failure of Primary Treatment of Chronic Central Serous ChorioretinopathyAmerican Journal of OphthalmologyVol. 222PreviewWe thank Drs Wu and Roca for their interest regarding our studies on chronic central serous chorioretinopathy (CSC), including the PLACE trial and the REPLACE trial.1,2 Full-Text PDF
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
